Lifesci Capital Issues Negative Outlook for TNYA Earnings

Key Points

• Analysts at Lifesci Capital have downgraded their earnings estimates for Tenaya Therapeutics (TNYA), predicting a loss of ($0.24) per share for Q2 2025, a revision from the previous estimate of ($0.18).
• Despite the negative outlook, Tenaya Therapeutics maintains a consensus rating of "Buy" from several analysts, with price targets ranging from $5.00 to $9.00.
• Currently, shares of TNYA are trading at around $0.67, and the company has been experiencing significant institutional investment, with 90.54% of the stock owned by institutional investors.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Stock analysts at Lifesci Capital reduced their Q2 2025 earnings per share estimates for shares of Tenaya Therapeutics in a research note issued on Thursday, July 31st. Lifesci Capital analyst C. Jubinville now forecasts that the company will post earnings of ($0.24) per share for the quarter, down from their previous estimate of ($0.18). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.96) EPS.

Other equities research analysts have also recently issued reports about the company. Chardan Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a research report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics presently has an average rating of "Buy" and a consensus price target of $6.25.

Tenaya Therapeutics Price Performance

NASDAQ:TNYA traded down $0.02 during mid-day trading on Monday, reaching $0.65. The stock had a trading volume of 1,180,395 shares, compared to its average volume of 2,769,305. The business's 50 day moving average is $0.66 and its 200 day moving average is $0.68. Tenaya Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $4.01. The stock has a market cap of $106.22 million, a P/E ratio of -0.58 and a beta of 3.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.06.

Institutional Investors Weigh In On Tenaya Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Woodline Partners LP lifted its stake in shares of Tenaya Therapeutics by 30,563.2% in the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after purchasing an additional 5,896,873 shares during the period. JPMorgan Chase & Co. raised its stake in Tenaya Therapeutics by 20,670.3% during the fourth quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company's stock valued at $7,373,000 after buying an additional 5,130,774 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Tenaya Therapeutics in the 1st quarter worth $442,000. Northern Trust Corp increased its holdings in shares of Tenaya Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 472,479 shares of the company's stock worth $676,000 after purchasing an additional 27,632 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in shares of Tenaya Therapeutics by 25.2% in the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company's stock worth $494,000 after purchasing an additional 69,377 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.